Saturn V Capital Management LP 13F holdings
Saturn V Capital Management LP reported 23 positions with a total reported value of $697.5M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: AMLX AMYLYX PHARMACEUTICALS INC (11.9%), ALMS ALUMIS INC (11.8%), ABVX ABIVAX SA (9.9%), PCVX VAXCYTE INC (7.1%), IMMX IMMIX BIOPHARMA INC (6.9%). Against 2026-03-31 it opened 3 new positions and exited 1. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when Saturn V Capital Management LP files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
23 largest of 23 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| AMLX AMYLYX PHARMACEUTICALS INC | 4,624,101 | $83.0M | 11.9% |
| ALMS ALUMIS INC | 2,915,443 | $82.0M | 11.8% |
| ABVX ABIVAX SA | 518,865 | $69.1M | 9.9% |
| PCVX VAXCYTE INC | 852,914 | $49.6M | 7.1% |
| IMMX IMMIX BIOPHARMA INC | 4,658,429 | $48.0M | 6.9% |
| PHVS PHARVARIS N V | 1,314,122 | $45.4M | 6.5% |
| JAZZ JAZZ PHARMACEUTICALS PLC | 160,938 | $38.8M | 5.6% |
| CELC CELCUITY INC | 370,318 | $38.7M | 5.6% |
| IRON DISC MEDICINE INC | 524,730 | $38.4M | 5.5% |
| CADL CANDEL THERAPEUTICS INC | 3,303,686 | $34.0M | 4.9% |
| XFOR X4 PHARMACEUTICALS INC | 6,973,343 | $32.6M | 4.7% |
| MNPR MONOPAR THERAPEUTICS INC | 311,976 | $28.9M | 4.1% |
| DYN DYNE THERAPEUTICS INC | 1,057,493 | $23.5M | 3.4% |
| TRVI TREVI THERAPEUTICS INC | 1,052,043 | $19.6M | 2.8% |
| ZURA ZURA BIO LTD | 2,101,119 | $12.4M | 1.8% |
| SGMT SAGIMET BIOSCIENCES INC | 1,479,918 | $11.4M | 1.6% |
| OCS OCULIS HOLDING AG | 684,880 | $9.5M | 1.4% |
| IKT INHIBIKASE THERAPEUTICS INC | 3,869,056 | $7.9M | 1.1% |
| VIR VIR BIOTECHNOLOGY INC | 770,643 | $7.9M | 1.1% |
| IVVD INVIVYD INC | 8,392,288 | $7.3M | 1.0% |
| ANRO ALTO NEUROSCIENCE INC | 182,829 | $4.8M | 0.7% |
| MSLE SATELLOS BIOSCIENCE INC | 350,000 | $2.7M | 0.4% |
| OVID OVID THERAPEUTICS INC | 663,060 | $1.8M | 0.3% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 3 in all · reported value as of 2026-06-30
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 1 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| COGT COGENT BIOSCIENCES INC | 626,635 | $24.1M | 4.4% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| IMMX IMMIX BIOPHARMA INC | 3,693,585 | 4,658,429 | +26.1% | $48.0M |
| CELC CELCUITY INC | 281,904 | 370,318 | +31.4% | $38.7M |
| ZURA ZURA BIO LTD | 739,960 | 2,101,119 | +184.0% | $12.4M |
| IRON DISC MEDICINE INC | 449,926 | 524,730 | +16.6% | $38.4M |
| AMLX AMYLYX PHARMACEUTICALS INC | 4,349,885 | 4,624,101 | +6.3% | $83.0M |
| CADL CANDEL THERAPEUTICS INC | 2,896,588 | 3,303,686 | +14.1% | $34.0M |
| PHVS PHARVARIS N V | 1,201,402 | 1,314,122 | +9.4% | $45.4M |
| ANRO ALTO NEUROSCIENCE INC | 88,999 | 182,829 | +105.4% | $4.8M |
| XFOR X4 PHARMACEUTICALS INC | 6,456,646 | 6,973,343 | +8.0% | $32.6M |
| OCS OCULIS HOLDING AG | 516,761 | 684,880 | +32.5% | $9.5M |
| DYN DYNE THERAPEUTICS INC | 966,609 | 1,057,493 | +9.4% | $23.5M |
| PCVX VAXCYTE INC | 824,532 | 852,914 | +3.4% | $49.6M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| OVID OVID THERAPEUTICS INC | 4,166,666 | 663,060 | -84.1% | $1.8M |
| ALMS ALUMIS INC | 3,202,075 | 2,915,443 | -9.0% | $82.0M |
| ABVX ABIVAX SA | 542,696 | 518,865 | -4.4% | $69.1M |
| MNPR MONOPAR THERAPEUTICS INC | 345,626 | 311,976 | -9.7% | $28.9M |
| IVVD INVIVYD INC | 10,949,084 | 8,392,288 | -23.4% | $7.3M |
| JAZZ JAZZ PHARMACEUTICALS PLC | 162,961 | 160,938 | -1.2% | $38.8M |
CIK 1964437 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
